A multicenter comparative study of brodimoprim and amoxicillin therapy in the treatment of tonsillopharyngitis in adults
Nyffenegger, R.; Riebenfeld, D.; Bandau, K.H.; Nouri, M.E.; Schirmböck, U.; Streppel, M.
Journal of ChemoTherapy 5(6): 512-516
1993
ISSN/ISBN: 1120-009X PMID: 8195847 Document Number: 419562
Study objective: To compare the efficacy and safety of brodimoprim (BDP) with those of amoxicillin (AMX) in patients with acute bacterial pharyngitis/tonsillitis. Design: Randomized controlled study. Setting: Hospital and general practices in Austria, Germany and Switzerland. Patients: 519 adult patients of both sexes aged 12 to 75 years. Intervention: Patients were allocated to an 8- to 12-day treatment with BDP (400 mg loading dose followed by 200mg once a day) or AMX (750 mg t.i.d). Main outcome measures: Resolution of clinical signs/symptoms and negative bacterial examination at completion of therapy. Results: Clinical cure/improvement rate of 97.8% and 94.8% in respectively the BDP and the AMX group. Bacterial eradication in 87.7% of the cases treated with BDP and 88.3% of those receiving AMX. very good/good tolerability in 85.2% BDP- and 82.8% AMX treated patients.